# Haisco

> Haisco is a VC fund in Wenxiang backing Health Care, Medical and Medical Device. See 5 investments, check sizes, portfolio. Updated Sep 2026.

- Type: VC Fund
- Location: Wenxiang, China
- Total investments: 5
- Last investment: Aug 2018
- Lead investor: 100%
- Last updated: Sep 2026
- Website: http://www.haisco.com/

Haisco is a VC fund in Wenxiang focused on Health Care and Medical. Haisco Pharmaceutical Group is a Chinese healthcare company focused on the research and development of therapeutic drugs.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 100% |
| Medical | 3 | 60% |
| Medical Device | 3 | 60% |
| Biotechnology | 2 | 40% |
| Pharmaceutical | 2 | 40% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 20% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Series D | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 3 | 60% |
| China | 1 | 20% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pneuma Respiratory | Pneuma Respiratory is a pharmaceutical company that creates digital solutions for respiratory drug delivery. It has created PNEUMAHALER, the first fully integrated digital breath activated inhaler. The inhaled delivery system has integrated Bluetooth technology to provide feedback on drug delivery to patients, family members and health careproviders. Using Pneuma's digital droplet ejector technology, Pneuma's device, although currently available for investigational purposes only, has the potential to ultimately deliver a spectrum of novel therapies, including biologics, through the lungs.Pneuma Respiratory was founded in 2015 and is headquartered in Boone, North Carolina, United States. | $10M | Venture - Series Unknown | Aug 14, 2018 |  |
| Laminate Medical | Laminate Medical Technologies is developing a new, external support device for AV fistulas, to be implanted during the fistula creation surgical procedure. The VasQ Device alleviates wall tension and regulates fistula geometry where an undesired narrowing of the vein and/or frequent blockages of the blood vessels may occur during the firstyear. Use of Laminate Medical Technology’s novel device aims to drive a change in the hemodialysis vascular access treatment paradigm and bring about a significant reduction in the annual fistula failure rate, thereby reducing kidney-failure related complications, re-interventions, and the cost burden of vascular access complications. | $8M | Series B | Feb 08, 2017 |  |
| Hinova Pharma | Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptorinhibitors and other products, for the treatment of advanced prostate cancer and breast cancer. |  | Series A | Nov 24, 2016 |  |
| Regentis Biomaterials | Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. DrorSeliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials. | $15M | Series D | Feb 07, 2016 |  |
| MST Medical Surgery Technologies | Medical Surgery Technologies (MST) was founded in 2005 by Ziv Tamir and Moti Sholev, entrepreneurs with extensive experience in medical devices. MST leads the field of surgical analytics with its core image analytics technology designed to empower and automate the surgical environment, with a focus on medical robotics and computer-assisted surgery(MRCAS).  The company's core technology is a software-based image analytics information platform powered by advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics. The platform is positioned to enable the operating room of the future through real-time image analytics, connectivity and automation, providing value-added functionality for surgeon, provider and patient. MST’s initial offering is AutoLap™, the only robotic image-guided laparoscope positioning system. Powered by MST’s image-analysis software, AutoLap™ interacts with the surgeon’s movements in the surgical cavity, guiding the robotic laparoscope positioner in real time, offering the surgeon full and natural control of the surgical procedure and an optimal field of view. | $12.5M | Series C | Jul 01, 2015 |  |

5 of 5 investments shown.

## Co-investors
- [SCP Vitalife Partners](https://shizune.co/investors/profile/scp-vitalife-partners) — VC Fund, 2 deals together
- [Agate Medical Investments](https://shizune.co/investors/profile/agate-medical-investments) — VC Fund, 1 deal together
- [Generali Investments Europe](https://shizune.co/investors/profile/generali-investments-europe) — VC Fund, 1 deal together
- Jacobs — VC Fund, 1 deal together
- Jacobs Ventures — VC Fund, 1 deal together
- Medica Venture Partners — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Haisco invest in?

Haisco invests primarily in Health Care, Medical and Medical Device startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Haisco last invest?

The most recent investment recorded for Haisco closed in Aug 2018. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co